Podcasts about ssc ild

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/circling-the-wagons-to-care-fibrosing-ilds-9649SummaryNavigating the challenges of fibrosing ILDs requires a team approach. In this podcast, explore the "Dream Team" of healthcare professionals who collaborate to address the diverse needs of patients with IPF, SSc-ILD, and PPF. From pulmonologists to therapists and beyond, uncover the critical roles each plays in managing comorbidities, symptoms, and overall well-being. Gain valuable insights on when to refer to a specialized ILD center for comprehensive care.Learning ObjectiveAt the conclusion of this activity, participants should be better able to:Integrate multidisciplinary management for patients with fibrosing ILDs to manage comorbidities and monitor for the need for specialty center referralThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours, which includes 0 hours of pharmacology.For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

#41. Oversiktsepisode. Introduksjon til ILD ved revmatoid artritt (RA-ILD), systemisk sklerose (SSc-ILD) og idiopatiske inflammatoriske myopatier (IIM-ILD, også kalt myositt-assosiert ILD (MA-ILD))Andre sesong er muliggjort gjennom et stipend fra Norsk revmatologisk forening. Hosted on Acast. See acast.com/privacy for more information.

Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com.  This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.

Go online to PeerView.com/TDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) or scleroderma is a rare, often fatal connective tissue disease that affects multiple organ systems. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Early diagnosis is key and relies on evaluation of signs and symptoms, pulmonary function tests, and high-resolution computed tomography. Until recently, therapy for SSc-ILD has been limited to supportive care and immunosuppressants. Fortunately, antifibrotic agents approved for idiopathic pulmonary fibrosis (IPF) have either received approval, or are in development, for SSc-ILD. Because SSc-ILD affects multiple organ systems and has many comorbidities, interprofessional management is essential from diagnosis throughout the disease course. In this expert-led activity, you will be able to self-assess your baseline levels of understanding, skill, and confidence, resulting in a tailored educational experience focused on the areas where you need it most. Upon completion of this activity, participants should be better able to: Diagnose SSc-ILD promptly and conduct comprehensive interprofessional assessments using clinical signs and symptoms, and guideline-directed testing, Use recent trial data and guidelines to guide the use of existing and emerging agents to treat SSc-ILD in an interprofessional care team, Leverage the interprofessional care team to manage the risk factors and comorbidities of SSc-ILD.

Go online to PeerView.com/TDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) or scleroderma is a rare, often fatal connective tissue disease that affects multiple organ systems. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Early diagnosis is key and relies on evaluation of signs and symptoms, pulmonary function tests, and high-resolution computed tomography. Until recently, therapy for SSc-ILD has been limited to supportive care and immunosuppressants. Fortunately, antifibrotic agents approved for idiopathic pulmonary fibrosis (IPF) have either received approval, or are in development, for SSc-ILD. Because SSc-ILD affects multiple organ systems and has many comorbidities, interprofessional management is essential from diagnosis throughout the disease course. In this expert-led activity, you will be able to self-assess your baseline levels of understanding, skill, and confidence, resulting in a tailored educational experience focused on the areas where you need it most. Upon completion of this activity, participants should be better able to: Diagnose SSc-ILD promptly and conduct comprehensive interprofessional assessments using clinical signs and symptoms, and guideline-directed testing, Use recent trial data and guidelines to guide the use of existing and emerging agents to treat SSc-ILD in an interprofessional care team, Leverage the interprofessional care team to manage the risk factors and comorbidities of SSc-ILD.

Go online to PeerView.com/TDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) or scleroderma is a rare, often fatal connective tissue disease that affects multiple organ systems. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Early diagnosis is key and relies on evaluation of signs and symptoms, pulmonary function tests, and high-resolution computed tomography. Until recently, therapy for SSc-ILD has been limited to supportive care and immunosuppressants. Fortunately, antifibrotic agents approved for idiopathic pulmonary fibrosis (IPF) have either received approval, or are in development, for SSc-ILD. Because SSc-ILD affects multiple organ systems and has many comorbidities, interprofessional management is essential from diagnosis throughout the disease course. In this expert-led activity, you will be able to self-assess your baseline levels of understanding, skill, and confidence, resulting in a tailored educational experience focused on the areas where you need it most. Upon completion of this activity, participants should be better able to: Diagnose SSc-ILD promptly and conduct comprehensive interprofessional assessments using clinical signs and symptoms, and guideline-directed testing, Use recent trial data and guidelines to guide the use of existing and emerging agents to treat SSc-ILD in an interprofessional care team, Leverage the interprofessional care team to manage the risk factors and comorbidities of SSc-ILD.

Go online to PeerView.com/TDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) or scleroderma is a rare, often fatal connective tissue disease that affects multiple organ systems. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Early diagnosis is key and relies on evaluation of signs and symptoms, pulmonary function tests, and high-resolution computed tomography. Until recently, therapy for SSc-ILD has been limited to supportive care and immunosuppressants. Fortunately, antifibrotic agents approved for idiopathic pulmonary fibrosis (IPF) have either received approval, or are in development, for SSc-ILD. Because SSc-ILD affects multiple organ systems and has many comorbidities, interprofessional management is essential from diagnosis throughout the disease course. In this expert-led activity, you will be able to self-assess your baseline levels of understanding, skill, and confidence, resulting in a tailored educational experience focused on the areas where you need it most. Upon completion of this activity, participants should be better able to: Diagnose SSc-ILD promptly and conduct comprehensive interprofessional assessments using clinical signs and symptoms, and guideline-directed testing, Use recent trial data and guidelines to guide the use of existing and emerging agents to treat SSc-ILD in an interprofessional care team, Leverage the interprofessional care team to manage the risk factors and comorbidities of SSc-ILD.

Go online to PeerView.com/TDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) or scleroderma is a rare, often fatal connective tissue disease that affects multiple organ systems. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Early diagnosis is key and relies on evaluation of signs and symptoms, pulmonary function tests, and high-resolution computed tomography. Until recently, therapy for SSc-ILD has been limited to supportive care and immunosuppressants. Fortunately, antifibrotic agents approved for idiopathic pulmonary fibrosis (IPF) have either received approval, or are in development, for SSc-ILD. Because SSc-ILD affects multiple organ systems and has many comorbidities, interprofessional management is essential from diagnosis throughout the disease course. In this expert-led activity, you will be able to self-assess your baseline levels of understanding, skill, and confidence, resulting in a tailored educational experience focused on the areas where you need it most. Upon completion of this activity, participants should be better able to: Diagnose SSc-ILD promptly and conduct comprehensive interprofessional assessments using clinical signs and symptoms, and guideline-directed testing, Use recent trial data and guidelines to guide the use of existing and emerging agents to treat SSc-ILD in an interprofessional care team, Leverage the interprofessional care team to manage the risk factors and comorbidities of SSc-ILD.

Go online to PeerView.com/TDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) or scleroderma is a rare, often fatal connective tissue disease that affects multiple organ systems. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Early diagnosis is key and relies on evaluation of signs and symptoms, pulmonary function tests, and high-resolution computed tomography. Until recently, therapy for SSc-ILD has been limited to supportive care and immunosuppressants. Fortunately, antifibrotic agents approved for idiopathic pulmonary fibrosis (IPF) have either received approval, or are in development, for SSc-ILD. Because SSc-ILD affects multiple organ systems and has many comorbidities, interprofessional management is essential from diagnosis throughout the disease course. In this expert-led activity, you will be able to self-assess your baseline levels of understanding, skill, and confidence, resulting in a tailored educational experience focused on the areas where you need it most. Upon completion of this activity, participants should be better able to: Diagnose SSc-ILD promptly and conduct comprehensive interprofessional assessments using clinical signs and symptoms, and guideline-directed testing, Use recent trial data and guidelines to guide the use of existing and emerging agents to treat SSc-ILD in an interprofessional care team, Leverage the interprofessional care team to manage the risk factors and comorbidities of SSc-ILD.

Go online to PeerView.com/MVH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in SSc-ILD discuss how to accurately interpret HRCT patterns, the latest diagnosis and management guidelines, including the importance of identifying and treating comorbidities, and the efficacy and safety of novel and emerging therapies. Upon completion of this CE activity, participants will be able to: Recognize signs, symptoms, and HRCT patterns indicative of ILD in patients with SSc and the importance of regular pulmonary monitoring in patients with SSc, Employ the latest guideline recommendations to the diagnosis and management of SSc-ILD in the context of an interprofessional approach, Apply the latest clinical evidence regarding efficacy and safety on novel and emerging therapies, including antifibrotic agents, to the treatment of SSc-ILD, Discuss the importance of assessing and managing comorbidities, such as gastroesophageal reflux disease and sleep apnea, in patients with SSc-ILD.

Go online to PeerView.com/MVH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in SSc-ILD discuss how to accurately interpret HRCT patterns, the latest diagnosis and management guidelines, including the importance of identifying and treating comorbidities, and the efficacy and safety of novel and emerging therapies. Upon completion of this CE activity, participants will be able to: Recognize signs, symptoms, and HRCT patterns indicative of ILD in patients with SSc and the importance of regular pulmonary monitoring in patients with SSc, Employ the latest guideline recommendations to the diagnosis and management of SSc-ILD in the context of an interprofessional approach, Apply the latest clinical evidence regarding efficacy and safety on novel and emerging therapies, including antifibrotic agents, to the treatment of SSc-ILD, Discuss the importance of assessing and managing comorbidities, such as gastroesophageal reflux disease and sleep apnea, in patients with SSc-ILD.

Go online to PeerView.com/MVH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in SSc-ILD discuss how to accurately interpret HRCT patterns, the latest diagnosis and management guidelines, including the importance of identifying and treating comorbidities, and the efficacy and safety of novel and emerging therapies. Upon completion of this CE activity, participants will be able to: Recognize signs, symptoms, and HRCT patterns indicative of ILD in patients with SSc and the importance of regular pulmonary monitoring in patients with SSc, Employ the latest guideline recommendations to the diagnosis and management of SSc-ILD in the context of an interprofessional approach, Apply the latest clinical evidence regarding efficacy and safety on novel and emerging therapies, including antifibrotic agents, to the treatment of SSc-ILD, Discuss the importance of assessing and managing comorbidities, such as gastroesophageal reflux disease and sleep apnea, in patients with SSc-ILD.

Go online to PeerView.com/MVH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in SSc-ILD discuss how to accurately interpret HRCT patterns, the latest diagnosis and management guidelines, including the importance of identifying and treating comorbidities, and the efficacy and safety of novel and emerging therapies. Upon completion of this CE activity, participants will be able to: Recognize signs, symptoms, and HRCT patterns indicative of ILD in patients with SSc and the importance of regular pulmonary monitoring in patients with SSc, Employ the latest guideline recommendations to the diagnosis and management of SSc-ILD in the context of an interprofessional approach, Apply the latest clinical evidence regarding efficacy and safety on novel and emerging therapies, including antifibrotic agents, to the treatment of SSc-ILD, Discuss the importance of assessing and managing comorbidities, such as gastroesophageal reflux disease and sleep apnea, in patients with SSc-ILD.

In this podcast, expert clinicians will discuss the strategies to improve patients adherence to therapy in SSc-ILD.

In this podcast, expert clinicians will discuss evidence-based recommendations for the treatment of SSc-ILD.

In this podcast, expert clinicians will discuss best practices in the diagnosis of SSc-ILD.

In this podcast, expert clinicians will discuss the prevalence and burden of SSc-ILD.

Go online to PeerView.com/XTM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in interstitial lung diseases discuss the signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD; how to interpret radiographic patterns on HRCT to facilitate an accurate diagnosis; and the importance of the multidisciplinary team. Upon completion of this activity, participants should be better able to: Describe signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD, that would warrant further evaluation, Interpret radiographic patterns on HRCT to facilitate the differential diagnosis of ILDs, including IPF, SSc-ILD, and CF-ILD, Discuss the use of HRCT to monitor disease progression in patients with ILD, Employ collaborative approaches as part of a multidisciplinary team to diagnose ILDs, including IPF, SSc-ILD, and CF-ILD.

Go online to PeerView.com/XTM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in interstitial lung diseases discuss the signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD; how to interpret radiographic patterns on HRCT to facilitate an accurate diagnosis; and the importance of the multidisciplinary team. Upon completion of this activity, participants should be better able to: Describe signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD, that would warrant further evaluation, Interpret radiographic patterns on HRCT to facilitate the differential diagnosis of ILDs, including IPF, SSc-ILD, and CF-ILD, Discuss the use of HRCT to monitor disease progression in patients with ILD, Employ collaborative approaches as part of a multidisciplinary team to diagnose ILDs, including IPF, SSc-ILD, and CF-ILD.

Go online to PeerView.com/XTM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in interstitial lung diseases discuss the signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD; how to interpret radiographic patterns on HRCT to facilitate an accurate diagnosis; and the importance of the multidisciplinary team. Upon completion of this activity, participants should be better able to: Describe signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD, that would warrant further evaluation, Interpret radiographic patterns on HRCT to facilitate the differential diagnosis of ILDs, including IPF, SSc-ILD, and CF-ILD, Discuss the use of HRCT to monitor disease progression in patients with ILD, Employ collaborative approaches as part of a multidisciplinary team to diagnose ILDs, including IPF, SSc-ILD, and CF-ILD.

Go online to PeerView.com/XTM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in interstitial lung diseases discuss the signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD; how to interpret radiographic patterns on HRCT to facilitate an accurate diagnosis; and the importance of the multidisciplinary team. Upon completion of this activity, participants should be better able to: Describe signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD, that would warrant further evaluation, Interpret radiographic patterns on HRCT to facilitate the differential diagnosis of ILDs, including IPF, SSc-ILD, and CF-ILD, Discuss the use of HRCT to monitor disease progression in patients with ILD, Employ collaborative approaches as part of a multidisciplinary team to diagnose ILDs, including IPF, SSc-ILD, and CF-ILD.

Go online to PeerView.com/XTM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in interstitial lung diseases discuss the signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD; how to interpret radiographic patterns on HRCT to facilitate an accurate diagnosis; and the importance of the multidisciplinary team. Upon completion of this activity, participants should be better able to: Describe signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD, that would warrant further evaluation, Interpret radiographic patterns on HRCT to facilitate the differential diagnosis of ILDs, including IPF, SSc-ILD, and CF-ILD, Discuss the use of HRCT to monitor disease progression in patients with ILD, Employ collaborative approaches as part of a multidisciplinary team to diagnose ILDs, including IPF, SSc-ILD, and CF-ILD.

Go online to PeerView.com/XTM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in interstitial lung diseases discuss the signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD; how to interpret radiographic patterns on HRCT to facilitate an accurate diagnosis; and the importance of the multidisciplinary team. Upon completion of this activity, participants should be better able to: Describe signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD, that would warrant further evaluation, Interpret radiographic patterns on HRCT to facilitate the differential diagnosis of ILDs, including IPF, SSc-ILD, and CF-ILD, Discuss the use of HRCT to monitor disease progression in patients with ILD, Employ collaborative approaches as part of a multidisciplinary team to diagnose ILDs, including IPF, SSc-ILD, and CF-ILD.

Go online to PeerView.com/XTM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in interstitial lung diseases discuss the signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD; how to interpret radiographic patterns on HRCT to facilitate an accurate diagnosis; and the importance of the multidisciplinary team. Upon completion of this activity, participants should be better able to: Describe signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD, that would warrant further evaluation, Interpret radiographic patterns on HRCT to facilitate the differential diagnosis of ILDs, including IPF, SSc-ILD, and CF-ILD, Discuss the use of HRCT to monitor disease progression in patients with ILD, Employ collaborative approaches as part of a multidisciplinary team to diagnose ILDs, including IPF, SSc-ILD, and CF-ILD.

Go online to PeerView.com/XTM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in interstitial lung diseases discuss the signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD; how to interpret radiographic patterns on HRCT to facilitate an accurate diagnosis; and the importance of the multidisciplinary team. Upon completion of this activity, participants should be better able to: Describe signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD, that would warrant further evaluation, Interpret radiographic patterns on HRCT to facilitate the differential diagnosis of ILDs, including IPF, SSc-ILD, and CF-ILD, Discuss the use of HRCT to monitor disease progression in patients with ILD, Employ collaborative approaches as part of a multidisciplinary team to diagnose ILDs, including IPF, SSc-ILD, and CF-ILD.

Toby Maher discusses the results of the SENSCIS trial, looking at the safety and efficacy of nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD) treated with mycophenolate.

Go online to PeerView.com/RUB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis is a rare connective-tissue disease that affects multiple organ systems and is characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Interstitial lung disease occurs in most patients with SSc and is now the primary cause of death in these patients. Treatment for SSc-ILD has historically been limited; however, novel therapies are now available and in development. At a recent live web broadcast, a panel of expert faculty offered insight to help clinicians achieve a greater understanding of the recognition, diagnosis, and management of SSc-ILD, including the latest clinical evidence on novel and emerging therapies. If you couldn't watch the live event, catch up with this on-demand version. Upon completion of this activity, participants should be better able to: Identify signs and symptoms of systemic sclerosis in patients initially presenting with clinical features indicative of interstitial lung disease, Discuss the importance of a multidisciplinary approach in the differential diagnosis and staging of SSc-ILD, Summarize the latest clinical efficacy and safety data on emerging therapies for SSc-ILD, including antifibrotic agents, Apply updated evidence-based recommendations for diagnosis, risk assessment, monitoring, and management of SSc-ILD.

Go online to PeerView.com/RUB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis is a rare connective-tissue disease that affects multiple organ systems and is characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Interstitial lung disease occurs in most patients with SSc and is now the primary cause of death in these patients. Treatment for SSc-ILD has historically been limited; however, novel therapies are now available and in development. At a recent live web broadcast, a panel of expert faculty offered insight to help clinicians achieve a greater understanding of the recognition, diagnosis, and management of SSc-ILD, including the latest clinical evidence on novel and emerging therapies. If you couldn't watch the live event, catch up with this on-demand version. Upon completion of this activity, participants should be better able to: Identify signs and symptoms of systemic sclerosis in patients initially presenting with clinical features indicative of interstitial lung disease, Discuss the importance of a multidisciplinary approach in the differential diagnosis and staging of SSc-ILD, Summarize the latest clinical efficacy and safety data on emerging therapies for SSc-ILD, including antifibrotic agents, Apply updated evidence-based recommendations for diagnosis, risk assessment, monitoring, and management of SSc-ILD.

Go online to PeerView.com/RUB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis is a rare connective-tissue disease that affects multiple organ systems and is characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Interstitial lung disease occurs in most patients with SSc and is now the primary cause of death in these patients. Treatment for SSc-ILD has historically been limited; however, novel therapies are now available and in development. At a recent live web broadcast, a panel of expert faculty offered insight to help clinicians achieve a greater understanding of the recognition, diagnosis, and management of SSc-ILD, including the latest clinical evidence on novel and emerging therapies. If you couldn't watch the live event, catch up with this on-demand version. Upon completion of this activity, participants should be better able to: Identify signs and symptoms of systemic sclerosis in patients initially presenting with clinical features indicative of interstitial lung disease, Discuss the importance of a multidisciplinary approach in the differential diagnosis and staging of SSc-ILD, Summarize the latest clinical efficacy and safety data on emerging therapies for SSc-ILD, including antifibrotic agents, Apply updated evidence-based recommendations for diagnosis, risk assessment, monitoring, and management of SSc-ILD.

Go online to PeerView.com/RUB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis is a rare connective-tissue disease that affects multiple organ systems and is characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Interstitial lung disease occurs in most patients with SSc and is now the primary cause of death in these patients. Treatment for SSc-ILD has historically been limited; however, novel therapies are now available and in development. At a recent live web broadcast, a panel of expert faculty offered insight to help clinicians achieve a greater understanding of the recognition, diagnosis, and management of SSc-ILD, including the latest clinical evidence on novel and emerging therapies. If you couldn't watch the live event, catch up with this on-demand version. Upon completion of this activity, participants should be better able to: Identify signs and symptoms of systemic sclerosis in patients initially presenting with clinical features indicative of interstitial lung disease, Discuss the importance of a multidisciplinary approach in the differential diagnosis and staging of SSc-ILD, Summarize the latest clinical efficacy and safety data on emerging therapies for SSc-ILD, including antifibrotic agents, Apply updated evidence-based recommendations for diagnosis, risk assessment, monitoring, and management of SSc-ILD.

Go online to PeerView.com/RUB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis is a rare connective-tissue disease that affects multiple organ systems and is characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Interstitial lung disease occurs in most patients with SSc and is now the primary cause of death in these patients. Treatment for SSc-ILD has historically been limited; however, novel therapies are now available and in development. At a recent live web broadcast, a panel of expert faculty offered insight to help clinicians achieve a greater understanding of the recognition, diagnosis, and management of SSc-ILD, including the latest clinical evidence on novel and emerging therapies. If you couldn't watch the live event, catch up with this on-demand version. Upon completion of this activity, participants should be better able to: Identify signs and symptoms of systemic sclerosis in patients initially presenting with clinical features indicative of interstitial lung disease, Discuss the importance of a multidisciplinary approach in the differential diagnosis and staging of SSc-ILD, Summarize the latest clinical efficacy and safety data on emerging therapies for SSc-ILD, including antifibrotic agents, Apply updated evidence-based recommendations for diagnosis, risk assessment, monitoring, and management of SSc-ILD.

Go online to PeerView.com/RUB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis is a rare connective-tissue disease that affects multiple organ systems and is characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Interstitial lung disease occurs in most patients with SSc and is now the primary cause of death in these patients. Treatment for SSc-ILD has historically been limited; however, novel therapies are now available and in development. At a recent live web broadcast, a panel of expert faculty offered insight to help clinicians achieve a greater understanding of the recognition, diagnosis, and management of SSc-ILD, including the latest clinical evidence on novel and emerging therapies. If you couldn't watch the live event, catch up with this on-demand version. Upon completion of this activity, participants should be better able to: Identify signs and symptoms of systemic sclerosis in patients initially presenting with clinical features indicative of interstitial lung disease, Discuss the importance of a multidisciplinary approach in the differential diagnosis and staging of SSc-ILD, Summarize the latest clinical efficacy and safety data on emerging therapies for SSc-ILD, including antifibrotic agents, Apply updated evidence-based recommendations for diagnosis, risk assessment, monitoring, and management of SSc-ILD.

Go online to PeerView.com/WPF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Based on a recent CME-certified MasterClass and Practicum live web broadcast, this on-demand program provides an overview of interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis, connective tissue disease–associated ILDs such as systemic sclerosis–associated ILD, and other chronic fibrosing ILDs associated with a progressive phenotype. The faculty highlight the associated signs and symptoms, heterogeneity, and challenges associated with the recognition of ILDs. The experts also share experiences and lessons from their own practices, offering practical strategies for the diagnosis of ILDs, with regard to the interpretation of high-resolution computed tomography images and the importance of multidisciplinary approaches to reach an accurate diagnosis to ensure prompt, appropriate treatment. Upon completion of this activity, participants should be better able to: Discuss the pathophysiology and signs and symptoms of ILDs, including IPF, SSc-ILD, and PF-ILD, Interpret radiographic patterns on HRCT to differentially diagnose ILDs, including IPF, SSc-ILD, and PF-ILD, Assess the latest clinical evidence on methods, including HRCT, to monitor disease progression in ILD and evaluate treatment response, Describe collaborative approaches as part of a multidisciplinary team to diagnose ILDs, including IPF, SSc-ILD, and PF-ILD.

Go online to PeerView.com/WPF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Based on a recent CME-certified MasterClass and Practicum live web broadcast, this on-demand program provides an overview of interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis, connective tissue disease–associated ILDs such as systemic sclerosis–associated ILD, and other chronic fibrosing ILDs associated with a progressive phenotype. The faculty highlight the associated signs and symptoms, heterogeneity, and challenges associated with the recognition of ILDs. The experts also share experiences and lessons from their own practices, offering practical strategies for the diagnosis of ILDs, with regard to the interpretation of high-resolution computed tomography images and the importance of multidisciplinary approaches to reach an accurate diagnosis to ensure prompt, appropriate treatment. Upon completion of this activity, participants should be better able to: Discuss the pathophysiology and signs and symptoms of ILDs, including IPF, SSc-ILD, and PF-ILD, Interpret radiographic patterns on HRCT to differentially diagnose ILDs, including IPF, SSc-ILD, and PF-ILD, Assess the latest clinical evidence on methods, including HRCT, to monitor disease progression in ILD and evaluate treatment response, Describe collaborative approaches as part of a multidisciplinary team to diagnose ILDs, including IPF, SSc-ILD, and PF-ILD.

Go online to PeerView.com/WPF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Based on a recent CME-certified MasterClass and Practicum live web broadcast, this on-demand program provides an overview of interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis, connective tissue disease–associated ILDs such as systemic sclerosis–associated ILD, and other chronic fibrosing ILDs associated with a progressive phenotype. The faculty highlight the associated signs and symptoms, heterogeneity, and challenges associated with the recognition of ILDs. The experts also share experiences and lessons from their own practices, offering practical strategies for the diagnosis of ILDs, with regard to the interpretation of high-resolution computed tomography images and the importance of multidisciplinary approaches to reach an accurate diagnosis to ensure prompt, appropriate treatment. Upon completion of this activity, participants should be better able to: Discuss the pathophysiology and signs and symptoms of ILDs, including IPF, SSc-ILD, and PF-ILD, Interpret radiographic patterns on HRCT to differentially diagnose ILDs, including IPF, SSc-ILD, and PF-ILD, Assess the latest clinical evidence on methods, including HRCT, to monitor disease progression in ILD and evaluate treatment response, Describe collaborative approaches as part of a multidisciplinary team to diagnose ILDs, including IPF, SSc-ILD, and PF-ILD.

Go online to PeerView.com/WPF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Based on a recent CME-certified MasterClass and Practicum live web broadcast, this on-demand program provides an overview of interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis, connective tissue disease–associated ILDs such as systemic sclerosis–associated ILD, and other chronic fibrosing ILDs associated with a progressive phenotype. The faculty highlight the associated signs and symptoms, heterogeneity, and challenges associated with the recognition of ILDs. The experts also share experiences and lessons from their own practices, offering practical strategies for the diagnosis of ILDs, with regard to the interpretation of high-resolution computed tomography images and the importance of multidisciplinary approaches to reach an accurate diagnosis to ensure prompt, appropriate treatment. Upon completion of this activity, participants should be better able to: Discuss the pathophysiology and signs and symptoms of ILDs, including IPF, SSc-ILD, and PF-ILD, Interpret radiographic patterns on HRCT to differentially diagnose ILDs, including IPF, SSc-ILD, and PF-ILD, Assess the latest clinical evidence on methods, including HRCT, to monitor disease progression in ILD and evaluate treatment response, Describe collaborative approaches as part of a multidisciplinary team to diagnose ILDs, including IPF, SSc-ILD, and PF-ILD.

Go online to PeerView.com/ZBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in interstitial lung disease discuss the latest clinical evidence for the use of antifibrotic therapy for ILDs. Upon completion of this activity, participants should be better able to: Recognize the prevalence and risk of interstitial lung disease (ILD) in patients with connective tissue diseases (CTDs), including systemic sclerosis (SSc)-associated ILD, Identify signs, symptoms, and patterns of ILD with a progressive phenotype in patients with CTDs, including SSc-ILD, Review current management, including treatment and recommendations for monitoring, as well as the latest clinical evidence for the use of antifibrotic therapy for ILDs associated with a progressive phenotype such as SSc-ILD, Discuss the importance of a multidisciplinary approach that includes rheumatologists to the diagnosis and management of ILDs associated with CTDs

Go online to PeerView.com/ZBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in interstitial lung disease discuss the latest clinical evidence for the use of antifibrotic therapy for ILDs. Upon completion of this activity, participants should be better able to: Recognize the prevalence and risk of interstitial lung disease (ILD) in patients with connective tissue diseases (CTDs), including systemic sclerosis (SSc)-associated ILD, Identify signs, symptoms, and patterns of ILD with a progressive phenotype in patients with CTDs, including SSc-ILD, Review current management, including treatment and recommendations for monitoring, as well as the latest clinical evidence for the use of antifibrotic therapy for ILDs associated with a progressive phenotype such as SSc-ILD, Discuss the importance of a multidisciplinary approach that includes rheumatologists to the diagnosis and management of ILDs associated with CTDs

Go online to PeerView.com/ZBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in interstitial lung disease discuss the latest clinical evidence for the use of antifibrotic therapy for ILDs. Upon completion of this activity, participants should be better able to: Recognize the prevalence and risk of interstitial lung disease (ILD) in patients with connective tissue diseases (CTDs), including systemic sclerosis (SSc)-associated ILD, Identify signs, symptoms, and patterns of ILD with a progressive phenotype in patients with CTDs, including SSc-ILD, Review current management, including treatment and recommendations for monitoring, as well as the latest clinical evidence for the use of antifibrotic therapy for ILDs associated with a progressive phenotype such as SSc-ILD, Discuss the importance of a multidisciplinary approach that includes rheumatologists to the diagnosis and management of ILDs associated with CTDs

Go online to PeerView.com/ZBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in interstitial lung disease discuss the latest clinical evidence for the use of antifibrotic therapy for ILDs. Upon completion of this activity, participants should be better able to: Recognize the prevalence and risk of interstitial lung disease (ILD) in patients with connective tissue diseases (CTDs), including systemic sclerosis (SSc)-associated ILD, Identify signs, symptoms, and patterns of ILD with a progressive phenotype in patients with CTDs, including SSc-ILD, Review current management, including treatment and recommendations for monitoring, as well as the latest clinical evidence for the use of antifibrotic therapy for ILDs associated with a progressive phenotype such as SSc-ILD, Discuss the importance of a multidisciplinary approach that includes rheumatologists to the diagnosis and management of ILDs associated with CTDs

Go online to PeerView.com/ZBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in interstitial lung disease discuss the latest clinical evidence for the use of antifibrotic therapy for ILDs. Upon completion of this activity, participants should be better able to: Recognize the prevalence and risk of interstitial lung disease (ILD) in patients with connective tissue diseases (CTDs), including systemic sclerosis (SSc)-associated ILD, Identify signs, symptoms, and patterns of ILD with a progressive phenotype in patients with CTDs, including SSc-ILD, Review current management, including treatment and recommendations for monitoring, as well as the latest clinical evidence for the use of antifibrotic therapy for ILDs associated with a progressive phenotype such as SSc-ILD, Discuss the importance of a multidisciplinary approach that includes rheumatologists to the diagnosis and management of ILDs associated with CTDs

Go online to PeerView.com/ZBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in interstitial lung disease discuss the latest clinical evidence for the use of antifibrotic therapy for ILDs. Upon completion of this activity, participants should be better able to: Recognize the prevalence and risk of interstitial lung disease (ILD) in patients with connective tissue diseases (CTDs), including systemic sclerosis (SSc)-associated ILD, Identify signs, symptoms, and patterns of ILD with a progressive phenotype in patients with CTDs, including SSc-ILD, Review current management, including treatment and recommendations for monitoring, as well as the latest clinical evidence for the use of antifibrotic therapy for ILDs associated with a progressive phenotype such as SSc-ILD, Discuss the importance of a multidisciplinary approach that includes rheumatologists to the diagnosis and management of ILDs associated with CTDs

This week I go back to a topic from episode 42, the SENSCIS trial and nintedanib for SSc-ILD.  The way this medication has been received and a recent article I wrote for The Rheumatologist gave me a nice jumping off point to cover a few more issues from this. Be sure to follow me @EBRheum to let me know what you think! The corresponding article is available here: https://www.the-rheumatologist.org/article/fda-approves-nintedanib-for-ssc-ild-but-temper-your-expectations/

Go online to PeerView.com/JGG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in interstitial lung diseases offers new insights for improving the diagnosis and management of ILD. Upon completion of this activity, participants will be able to: Outline the prevalence, burden of illness, and signs and symptoms of interstitial lung disease (ILD), including IPF and SSc-ILD, Employ updated guidelines and best practices for differential diagnosis of ILD, including IPF, Evaluate current and emerging strategies for the management of ILD, including IPF and SSc-ILD, Implement evidence-based strategies to manage IPF, mitigate adverse events related to antifibrotic therapy, manage comorbid disease, and improve quality of life, Apply methods to effectively communicate and educate ILD patients about their disease.

Go online to PeerView.com/JGG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in interstitial lung diseases offers new insights for improving the diagnosis and management of ILD. Upon completion of this activity, participants will be able to: Outline the prevalence, burden of illness, and signs and symptoms of interstitial lung disease (ILD), including IPF and SSc-ILD, Employ updated guidelines and best practices for differential diagnosis of ILD, including IPF, Evaluate current and emerging strategies for the management of ILD, including IPF and SSc-ILD, Implement evidence-based strategies to manage IPF, mitigate adverse events related to antifibrotic therapy, manage comorbid disease, and improve quality of life, Apply methods to effectively communicate and educate ILD patients about their disease.

Go online to PeerView.com/JGG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in interstitial lung diseases offers new insights for improving the diagnosis and management of ILD. Upon completion of this activity, participants will be able to: Outline the prevalence, burden of illness, and signs and symptoms of interstitial lung disease (ILD), including IPF and SSc-ILD, Employ updated guidelines and best practices for differential diagnosis of ILD, including IPF, Evaluate current and emerging strategies for the management of ILD, including IPF and SSc-ILD, Implement evidence-based strategies to manage IPF, mitigate adverse events related to antifibrotic therapy, manage comorbid disease, and improve quality of life, Apply methods to effectively communicate and educate ILD patients about their disease.

Go online to PeerView.com/JGG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in interstitial lung diseases offers new insights for improving the diagnosis and management of ILD. Upon completion of this activity, participants will be able to: Outline the prevalence, burden of illness, and signs and symptoms of interstitial lung disease (ILD), including IPF and SSc-ILD, Employ updated guidelines and best practices for differential diagnosis of ILD, including IPF, Evaluate current and emerging strategies for the management of ILD, including IPF and SSc-ILD, Implement evidence-based strategies to manage IPF, mitigate adverse events related to antifibrotic therapy, manage comorbid disease, and improve quality of life, Apply methods to effectively communicate and educate ILD patients about their disease.

Go online to PeerView.com/JGG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in interstitial lung diseases offers new insights for improving the diagnosis and management of ILD. Upon completion of this activity, participants will be able to: Outline the prevalence, burden of illness, and signs and symptoms of interstitial lung disease (ILD), including IPF and SSc-ILD, Employ updated guidelines and best practices for differential diagnosis of ILD, including IPF, Evaluate current and emerging strategies for the management of ILD, including IPF and SSc-ILD, Implement evidence-based strategies to manage IPF, mitigate adverse events related to antifibrotic therapy, manage comorbid disease, and improve quality of life, Apply methods to effectively communicate and educate ILD patients about their disease.

Go online to PeerView.com/JGG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in interstitial lung diseases offers new insights for improving the diagnosis and management of ILD. Upon completion of this activity, participants will be able to: Outline the prevalence, burden of illness, and signs and symptoms of interstitial lung disease (ILD), including IPF and SSc-ILD, Employ updated guidelines and best practices for differential diagnosis of ILD, including IPF, Evaluate current and emerging strategies for the management of ILD, including IPF and SSc-ILD, Implement evidence-based strategies to manage IPF, mitigate adverse events related to antifibrotic therapy, manage comorbid disease, and improve quality of life, Apply methods to effectively communicate and educate ILD patients about their disease.

Go online to PeerView.com/UBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, often fatal, connective tissue disease that affects multiple organ systems. Early diagnosis, and thus earlier treatment, is critical to prevent disease progression, with its irreversible fibrosis and organ damage. In particular, regular monitoring for lung involvement, especially interstitial lung disease (ILD), is vital, as ILD occurs in the majority of patients with SSc and is now the number one cause of death in these patients. Treatment for SSc-associated ILD has historically been limited, with no FDA-approved options; however, novel therapies have shown promise in clinical trials. In this PeerView MasterClass, a panel of expert faculty offer insight into the pathogenesis of SSc-associated ILD, the burden of disease on patient quality of life, and diagnostic modalities and challenges. The faculty also discuss risk factors associated with disease progression and severity, current and emerging therapies, and the importance of multidisciplinary treatment and effective patient/provider communication to optimize patient outcomes. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms of systemic sclerosis (SSc) to facilitate earlier diagnosis and treatment to help prevent disease progression, Assess the relationship between disease pathophysiology and the signs and symptoms of systemic sclerosis-interstitial lung disease (SSc-ILD) and the need for timely screening to initiate appropriate treatment, Employ the latest evidence-based recommendations for diagnosis, risk assessment, and management of SSc-ILD, Evaluate emerging therapies for the treatment of SSc-ILD in terms of their efficacy and safety, Communicate effectively with patients to provide them with disease- and treatment-related education.

Go online to PeerView.com/UBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, often fatal, connective tissue disease that affects multiple organ systems. Early diagnosis, and thus earlier treatment, is critical to prevent disease progression, with its irreversible fibrosis and organ damage. In particular, regular monitoring for lung involvement, especially interstitial lung disease (ILD), is vital, as ILD occurs in the majority of patients with SSc and is now the number one cause of death in these patients. Treatment for SSc-associated ILD has historically been limited, with no FDA-approved options; however, novel therapies have shown promise in clinical trials. In this PeerView MasterClass, a panel of expert faculty offer insight into the pathogenesis of SSc-associated ILD, the burden of disease on patient quality of life, and diagnostic modalities and challenges. The faculty also discuss risk factors associated with disease progression and severity, current and emerging therapies, and the importance of multidisciplinary treatment and effective patient/provider communication to optimize patient outcomes. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms of systemic sclerosis (SSc) to facilitate earlier diagnosis and treatment to help prevent disease progression, Assess the relationship between disease pathophysiology and the signs and symptoms of systemic sclerosis-interstitial lung disease (SSc-ILD) and the need for timely screening to initiate appropriate treatment, Employ the latest evidence-based recommendations for diagnosis, risk assessment, and management of SSc-ILD, Evaluate emerging therapies for the treatment of SSc-ILD in terms of their efficacy and safety, Communicate effectively with patients to provide them with disease- and treatment-related education.

Go online to PeerView.com/UBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, often fatal, connective tissue disease that affects multiple organ systems. Early diagnosis, and thus earlier treatment, is critical to prevent disease progression, with its irreversible fibrosis and organ damage. In particular, regular monitoring for lung involvement, especially interstitial lung disease (ILD), is vital, as ILD occurs in the majority of patients with SSc and is now the number one cause of death in these patients. Treatment for SSc-associated ILD has historically been limited, with no FDA-approved options; however, novel therapies have shown promise in clinical trials. In this PeerView MasterClass, a panel of expert faculty offer insight into the pathogenesis of SSc-associated ILD, the burden of disease on patient quality of life, and diagnostic modalities and challenges. The faculty also discuss risk factors associated with disease progression and severity, current and emerging therapies, and the importance of multidisciplinary treatment and effective patient/provider communication to optimize patient outcomes. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms of systemic sclerosis (SSc) to facilitate earlier diagnosis and treatment to help prevent disease progression, Assess the relationship between disease pathophysiology and the signs and symptoms of systemic sclerosis-interstitial lung disease (SSc-ILD) and the need for timely screening to initiate appropriate treatment, Employ the latest evidence-based recommendations for diagnosis, risk assessment, and management of SSc-ILD, Evaluate emerging therapies for the treatment of SSc-ILD in terms of their efficacy and safety, Communicate effectively with patients to provide them with disease- and treatment-related education.

Go online to PeerView.com/UBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, often fatal, connective tissue disease that affects multiple organ systems. Early diagnosis, and thus earlier treatment, is critical to prevent disease progression, with its irreversible fibrosis and organ damage. In particular, regular monitoring for lung involvement, especially interstitial lung disease (ILD), is vital, as ILD occurs in the majority of patients with SSc and is now the number one cause of death in these patients. Treatment for SSc-associated ILD has historically been limited, with no FDA-approved options; however, novel therapies have shown promise in clinical trials. In this PeerView MasterClass, a panel of expert faculty offer insight into the pathogenesis of SSc-associated ILD, the burden of disease on patient quality of life, and diagnostic modalities and challenges. The faculty also discuss risk factors associated with disease progression and severity, current and emerging therapies, and the importance of multidisciplinary treatment and effective patient/provider communication to optimize patient outcomes. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms of systemic sclerosis (SSc) to facilitate earlier diagnosis and treatment to help prevent disease progression, Assess the relationship between disease pathophysiology and the signs and symptoms of systemic sclerosis-interstitial lung disease (SSc-ILD) and the need for timely screening to initiate appropriate treatment, Employ the latest evidence-based recommendations for diagnosis, risk assessment, and management of SSc-ILD, Evaluate emerging therapies for the treatment of SSc-ILD in terms of their efficacy and safety, Communicate effectively with patients to provide them with disease- and treatment-related education.

Go online to PeerView.com/UBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, often fatal, connective tissue disease that affects multiple organ systems. Early diagnosis, and thus earlier treatment, is critical to prevent disease progression, with its irreversible fibrosis and organ damage. In particular, regular monitoring for lung involvement, especially interstitial lung disease (ILD), is vital, as ILD occurs in the majority of patients with SSc and is now the number one cause of death in these patients. Treatment for SSc-associated ILD has historically been limited, with no FDA-approved options; however, novel therapies have shown promise in clinical trials. In this PeerView MasterClass, a panel of expert faculty offer insight into the pathogenesis of SSc-associated ILD, the burden of disease on patient quality of life, and diagnostic modalities and challenges. The faculty also discuss risk factors associated with disease progression and severity, current and emerging therapies, and the importance of multidisciplinary treatment and effective patient/provider communication to optimize patient outcomes. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms of systemic sclerosis (SSc) to facilitate earlier diagnosis and treatment to help prevent disease progression, Assess the relationship between disease pathophysiology and the signs and symptoms of systemic sclerosis-interstitial lung disease (SSc-ILD) and the need for timely screening to initiate appropriate treatment, Employ the latest evidence-based recommendations for diagnosis, risk assessment, and management of SSc-ILD, Evaluate emerging therapies for the treatment of SSc-ILD in terms of their efficacy and safety, Communicate effectively with patients to provide them with disease- and treatment-related education.

Go online to PeerView.com/UBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, often fatal, connective tissue disease that affects multiple organ systems. Early diagnosis, and thus earlier treatment, is critical to prevent disease progression, with its irreversible fibrosis and organ damage. In particular, regular monitoring for lung involvement, especially interstitial lung disease (ILD), is vital, as ILD occurs in the majority of patients with SSc and is now the number one cause of death in these patients. Treatment for SSc-associated ILD has historically been limited, with no FDA-approved options; however, novel therapies have shown promise in clinical trials. In this PeerView MasterClass, a panel of expert faculty offer insight into the pathogenesis of SSc-associated ILD, the burden of disease on patient quality of life, and diagnostic modalities and challenges. The faculty also discuss risk factors associated with disease progression and severity, current and emerging therapies, and the importance of multidisciplinary treatment and effective patient/provider communication to optimize patient outcomes. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms of systemic sclerosis (SSc) to facilitate earlier diagnosis and treatment to help prevent disease progression, Assess the relationship between disease pathophysiology and the signs and symptoms of systemic sclerosis-interstitial lung disease (SSc-ILD) and the need for timely screening to initiate appropriate treatment, Employ the latest evidence-based recommendations for diagnosis, risk assessment, and management of SSc-ILD, Evaluate emerging therapies for the treatment of SSc-ILD in terms of their efficacy and safety, Communicate effectively with patients to provide them with disease- and treatment-related education.

Exciting episode this week!  This is the FIRST of a new podcast series entitled Rheum4Debate, an Oxford style debate show for the field of rheumatology.  We are planning to release one episode a month; each have a moderator and one physician on each side of a controversial motion.  Be sure to VOTE on whether you agree or disagree with the motion AFTER you have listened to the podcast! Get the episode at ebrheum.com!

Go online to PeerView.com/RWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, clinically heterogeneous, multisystem disease characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Before 2019, immunosuppression was the mainstay of treatment; however, the recent FDA approval of the first antifibrotic agent specifically for the treatment of SSc-ILD now offers a new avenue of therapy for these patients. Evidence has shown that a multidisciplinary discussion—particularly the input of rheumatologists—often changes a diagnosis to one of the connective tissue disease–associated ILDs, including SSc-ILD, and consequently, the prognosis and treatment. This PeerView web broadcast underscores the importance of this collaboration and the best practices in the management of SSc-ILD. Our expert panel discusses the latest clinical data on antifibrotic therapy for SSc-ILD, as well as evidence-based treatment and recommendations for monitoring disease progression. Upon completion of this activity, participants should be better able to: Identify signs, symptoms, and patterns of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc), Recognize the importance of collaborating with other specialists in the diagnosis and management of SSc-ILD, Summarize the latest clinical data regarding efficacy and safety for the use of antifibrotic therapy for SSc-ILD, Apply best practices to the management of SSc-ILD, including evidence-based treatment and recommendations for monitoring disease progression.

Go online to PeerView.com/RWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, clinically heterogeneous, multisystem disease characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Before 2019, immunosuppression was the mainstay of treatment; however, the recent FDA approval of the first antifibrotic agent specifically for the treatment of SSc-ILD now offers a new avenue of therapy for these patients. Evidence has shown that a multidisciplinary discussion—particularly the input of rheumatologists—often changes a diagnosis to one of the connective tissue disease–associated ILDs, including SSc-ILD, and consequently, the prognosis and treatment. This PeerView web broadcast underscores the importance of this collaboration and the best practices in the management of SSc-ILD. Our expert panel discusses the latest clinical data on antifibrotic therapy for SSc-ILD, as well as evidence-based treatment and recommendations for monitoring disease progression. Upon completion of this activity, participants should be better able to: Identify signs, symptoms, and patterns of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc), Recognize the importance of collaborating with other specialists in the diagnosis and management of SSc-ILD, Summarize the latest clinical data regarding efficacy and safety for the use of antifibrotic therapy for SSc-ILD, Apply best practices to the management of SSc-ILD, including evidence-based treatment and recommendations for monitoring disease progression.

Go online to PeerView.com/RWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, clinically heterogeneous, multisystem disease characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Before 2019, immunosuppression was the mainstay of treatment; however, the recent FDA approval of the first antifibrotic agent specifically for the treatment of SSc-ILD now offers a new avenue of therapy for these patients. Evidence has shown that a multidisciplinary discussion—particularly the input of rheumatologists—often changes a diagnosis to one of the connective tissue disease–associated ILDs, including SSc-ILD, and consequently, the prognosis and treatment. This PeerView web broadcast underscores the importance of this collaboration and the best practices in the management of SSc-ILD. Our expert panel discusses the latest clinical data on antifibrotic therapy for SSc-ILD, as well as evidence-based treatment and recommendations for monitoring disease progression. Upon completion of this activity, participants should be better able to: Identify signs, symptoms, and patterns of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc), Recognize the importance of collaborating with other specialists in the diagnosis and management of SSc-ILD, Summarize the latest clinical data regarding efficacy and safety for the use of antifibrotic therapy for SSc-ILD, Apply best practices to the management of SSc-ILD, including evidence-based treatment and recommendations for monitoring disease progression.

Go online to PeerView.com/RWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, clinically heterogeneous, multisystem disease characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Before 2019, immunosuppression was the mainstay of treatment; however, the recent FDA approval of the first antifibrotic agent specifically for the treatment of SSc-ILD now offers a new avenue of therapy for these patients. Evidence has shown that a multidisciplinary discussion—particularly the input of rheumatologists—often changes a diagnosis to one of the connective tissue disease–associated ILDs, including SSc-ILD, and consequently, the prognosis and treatment. This PeerView web broadcast underscores the importance of this collaboration and the best practices in the management of SSc-ILD. Our expert panel discusses the latest clinical data on antifibrotic therapy for SSc-ILD, as well as evidence-based treatment and recommendations for monitoring disease progression. Upon completion of this activity, participants should be better able to: Identify signs, symptoms, and patterns of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc), Recognize the importance of collaborating with other specialists in the diagnosis and management of SSc-ILD, Summarize the latest clinical data regarding efficacy and safety for the use of antifibrotic therapy for SSc-ILD, Apply best practices to the management of SSc-ILD, including evidence-based treatment and recommendations for monitoring disease progression.

Go online to PeerView.com/RWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, clinically heterogeneous, multisystem disease characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Before 2019, immunosuppression was the mainstay of treatment; however, the recent FDA approval of the first antifibrotic agent specifically for the treatment of SSc-ILD now offers a new avenue of therapy for these patients. Evidence has shown that a multidisciplinary discussion—particularly the input of rheumatologists—often changes a diagnosis to one of the connective tissue disease–associated ILDs, including SSc-ILD, and consequently, the prognosis and treatment. This PeerView web broadcast underscores the importance of this collaboration and the best practices in the management of SSc-ILD. Our expert panel discusses the latest clinical data on antifibrotic therapy for SSc-ILD, as well as evidence-based treatment and recommendations for monitoring disease progression. Upon completion of this activity, participants should be better able to: Identify signs, symptoms, and patterns of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc), Recognize the importance of collaborating with other specialists in the diagnosis and management of SSc-ILD, Summarize the latest clinical data regarding efficacy and safety for the use of antifibrotic therapy for SSc-ILD, Apply best practices to the management of SSc-ILD, including evidence-based treatment and recommendations for monitoring disease progression.

Go online to PeerView.com/RWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, clinically heterogeneous, multisystem disease characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Before 2019, immunosuppression was the mainstay of treatment; however, the recent FDA approval of the first antifibrotic agent specifically for the treatment of SSc-ILD now offers a new avenue of therapy for these patients. Evidence has shown that a multidisciplinary discussion—particularly the input of rheumatologists—often changes a diagnosis to one of the connective tissue disease–associated ILDs, including SSc-ILD, and consequently, the prognosis and treatment. This PeerView web broadcast underscores the importance of this collaboration and the best practices in the management of SSc-ILD. Our expert panel discusses the latest clinical data on antifibrotic therapy for SSc-ILD, as well as evidence-based treatment and recommendations for monitoring disease progression. Upon completion of this activity, participants should be better able to: Identify signs, symptoms, and patterns of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc), Recognize the importance of collaborating with other specialists in the diagnosis and management of SSc-ILD, Summarize the latest clinical data regarding efficacy and safety for the use of antifibrotic therapy for SSc-ILD, Apply best practices to the management of SSc-ILD, including evidence-based treatment and recommendations for monitoring disease progression.

Go online to PeerView.com/RWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, clinically heterogeneous, multisystem disease characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Before 2019, immunosuppression was the mainstay of treatment; however, the recent FDA approval of the first antifibrotic agent specifically for the treatment of SSc-ILD now offers a new avenue of therapy for these patients. Evidence has shown that a multidisciplinary discussion—particularly the input of rheumatologists—often changes a diagnosis to one of the connective tissue disease–associated ILDs, including SSc-ILD, and consequently, the prognosis and treatment. This PeerView web broadcast underscores the importance of this collaboration and the best practices in the management of SSc-ILD. Our expert panel discusses the latest clinical data on antifibrotic therapy for SSc-ILD, as well as evidence-based treatment and recommendations for monitoring disease progression. Upon completion of this activity, participants should be better able to: Identify signs, symptoms, and patterns of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc), Recognize the importance of collaborating with other specialists in the diagnosis and management of SSc-ILD, Summarize the latest clinical data regarding efficacy and safety for the use of antifibrotic therapy for SSc-ILD, Apply best practices to the management of SSc-ILD, including evidence-based treatment and recommendations for monitoring disease progression.

Go online to PeerView.com/RWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, clinically heterogeneous, multisystem disease characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Before 2019, immunosuppression was the mainstay of treatment; however, the recent FDA approval of the first antifibrotic agent specifically for the treatment of SSc-ILD now offers a new avenue of therapy for these patients. Evidence has shown that a multidisciplinary discussion—particularly the input of rheumatologists—often changes a diagnosis to one of the connective tissue disease–associated ILDs, including SSc-ILD, and consequently, the prognosis and treatment. This PeerView web broadcast underscores the importance of this collaboration and the best practices in the management of SSc-ILD. Our expert panel discusses the latest clinical data on antifibrotic therapy for SSc-ILD, as well as evidence-based treatment and recommendations for monitoring disease progression. Upon completion of this activity, participants should be better able to: Identify signs, symptoms, and patterns of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc), Recognize the importance of collaborating with other specialists in the diagnosis and management of SSc-ILD, Summarize the latest clinical data regarding efficacy and safety for the use of antifibrotic therapy for SSc-ILD, Apply best practices to the management of SSc-ILD, including evidence-based treatment and recommendations for monitoring disease progression.